Compounded Semaglutide Market Trends: Brand Efficacy, Safety, and Regulatory Analysis
Title: Compounded Semaglutide Market Trends: Brand Efficacy, Safety, and Regulatory Analysis Abstract: The compounded semaglutide market is surging due to brand drug shortages and cost barriers, yet faces critical safety and regulatory scrutiny. Unlike patented GLP-1 receptor agonists (e.g., Ozempic, Wegovy), compounded versions lack FDA approval, posing purity and dosing risks. Market data indicates 40% of patients seek alternatives for weight management and diabetes, driving demand for rigorous factory GMP certifications and third-party testing. Key differentiators include peptide purity (>99%), stability, and cold-chain logistics compliance. While offering affordability, compounded products require careful selection based on certificate of analysis (CoA) and regulatory adherence to mitigate adverse events.